AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23440247 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 µg once daily
Number of subjects: 0
Study 23440247 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 µg once daily
Number of subjects: 0
Study 23440247 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 µg twice daily
Number of subjects: 0
Study 21309841 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic feedback system to general practitioners
Number of subjects: 2458
Study 21309841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic feedback)
Number of subjects: 2458
Study 18958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + fortified milk
Number of subjects: 180
Study 18958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 180
Study 18958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 180
Study 18958384 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 180
Study 16704995 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 113
Study 16704995 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 113
Study 15224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-uterine system releasing 10 micrograms/day levonorgestrel and 2 mg oral estradiol (trial 1)
Number of subjects: 94
Study 15224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine system releasing 20 micrograms/day levonorgestrel and 2 mg estradiol (trial 2)
Number of subjects: 94
Study 15224654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 mg norethisterone acetate and 2 mg estradiol (trial 2)
Number of subjects: 94
Study 11218416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration involvement
Number of subjects: 0
Study 11218416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration and EBM recognition
Number of subjects: 0
Study 9203809 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 1,500 mg acute dose
Number of subjects: 12
Study 9203809 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 750 mg t.i.d. for 15 days
Number of subjects: 12
Study 9203809 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 750 mg t.i.d. for 30 days
Number of subjects: 12
Study 9203809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7951791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary model including clinical and ergonomic interventions
Number of subjects: 79
Study 7951791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic and clinical interventions
Number of subjects: 79
Study 2735733 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg per day of trimetazidine (TMZ)
Number of subjects: 20
Study 2735733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study 30674586 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lipopolysaccharide (LPS) 50 µg
Number of subjects: 38
Study 30674586 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline
Number of subjects: 38
Study 30674586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 38
Study 30674586 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat radiolabelling/imaging in COPD patients
Number of subjects: 38
Study 30674586 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge
Number of subjects: 38
Study 28403554 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemofiltration (CVVH)
Number of subjects: 120
Study 28403554 — intervention group
Group type: COMPARATOR
Intervention: Slow continuous ultrafiltration (SCUF)
Number of subjects: 120
Study 26136484 — intervention group
Group type: EXPERIMENTAL
Intervention: Video ON
Number of subjects: 3017
Study 26136484 — intervention group
Group type: COMPARATOR
Intervention: Video OFF
Number of subjects: 3017
Study 26136484 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated video viewing
Number of subjects: 3017
Study 26136484 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated video viewing
Number of subjects: 3017
Study 23387398 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 120
Study 21693044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy with night-splinting
Number of subjects: 154
Study 21693044 — intervention group
Group type: COMPARATOR
Intervention: Hand therapy only
Number of subjects: 154
Study 18516681 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care prevention operating system
Number of subjects: 24
Study 18516681 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 24
Study 16456637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent glycerine trinitrate ointment applied three times daily at the anal margin for eight weeks (Group A)
Number of subjects: 30
Study 16456637 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units Botulinum toxin A injection into the internal anal sphincter on each side of the anterior midline (Group B)
Number of subjects: 30
Study 15383188 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus hypocaloric diet (HCD)
Number of subjects: 126
Study 15383188 — intervention group
Group type: COMPARATOR
Intervention: HCD alone
Number of subjects: 126
Study 11146152 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Utrecht Octopus Method)
Number of subjects: 560
Study 11146152 — intervention group
Group type: COMPARATOR
Intervention: Repeat angiography at 1 year
Number of subjects: 560
Study 8618654 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 2000000
Study 1634914 — intervention group
Group type: COMPARATOR
Intervention: LOPP
Number of subjects: 594
Study 1634914 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPP/EVAP
Number of subjects: 594
Study 6373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 103
Study 6373644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 103
Study 6373644 — intervention group
Group type: COMPARATOR
Intervention: No-surgery group
Number of subjects: 103
Study 30109585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Services (TS) program (n = 935)
Number of subjects: 1876
Study 30109585 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 941)
Number of subjects: 1876
Study 28777245 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Shot (ES)
Number of subjects: 10
Study 28777245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: ED 50 of intrathecal bupivacaine
Number of subjects: 200
Study 25635420 — intervention group
Group type: EXPERIMENTAL
Intervention: ED 95 of intrathecal bupivacaine
Number of subjects: 200
Study 25635420 — intervention group
Group type: COMPARATOR
Intervention: Overall satisfaction and newborns' Apgar score
Number of subjects: 200
Study 24996507 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs (eicosapentaenoic acid 2g/day and docosahexaenoic acid 1g/day) + α‐LA 300 mg/day
Number of subjects: 33
Study 24996507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21848460 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 6041
Study 21848460 — intervention group
Group type: COMPARATOR
Intervention: ETAC-guided anesthesia
Number of subjects: 6041
Study 18414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum carotenoid concentrations measured in participants over 4 years
Number of subjects: 1905
Study 18414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene measurement
Number of subjects: 1905
Study 18414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin and beta-carotene measurements
Number of subjects: 1905
Study 18414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Center and center-by-season effects
Number of subjects: 1905
Study 18414504 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood measurements
Number of subjects: 1905
Study 17209178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic load meal
Number of subjects: 16
Study 17209178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load meal
Number of subjects: 16
Study 15179406 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-773 450 mg in CYP3A5-negative subjects (n = 9)
Number of subjects: 17
Study 15179406 — intervention group
Group type: COMPARATOR
Intervention: ABT-773 450 mg in CYP3A5-positive subjects (n = 8)
Number of subjects: 17
Study 15179406 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-773 150 mg or 300 mg
Number of subjects: 17
Study 11455374 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish in combination with fluoride varnish (group 1)
Number of subjects: 220
Study 11455374 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish alone (group 2)
Number of subjects: 220
Study 11455374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antimicrobial and fluoride varnishes
Number of subjects: 220
Study 11455374 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish
Number of subjects: 220
Study 9543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day, n = 16)
Number of subjects: 30
Study 9543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day, n = 14)
Number of subjects: 30
Study 8053353 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 8053353 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 0
Study 2726331 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (10 micrograms of hepatitis B vaccine at 0, 1, 2, and 11 months)
Number of subjects: 180
Study 2726331 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (10 micrograms of hepatitis B vaccine at 3, 4, 5, and 11 months)
Number of subjects: 180
Study 30885407 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 87
Study 30885407 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PA)
Number of subjects: 87
Study 29017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (telephone and in-person)
Number of subjects: 100
Study 29017589 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 100
Study 29017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 100
Study 29017589 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 26471805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 480
Study 26471805 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 480
Study 26471805 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 480
Study 26471805 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 480
Study 23530695 — intervention group
Group type: EXPERIMENTAL
Intervention: Student before Doctor
Number of subjects: 151
Study 23530695 — intervention group
Group type: COMPARATOR
Intervention: No Student
Number of subjects: 151
Study 23530695 — intervention group
Group type: COMPARATOR
Intervention: Student with Doctor
Number of subjects: 151
Study 21592131 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled school nurse inspections
Number of subjects: 0
Study 21592131 — intervention group
Group type: COMPARATOR
Intervention: Control group reporting to NMDOH only
Number of subjects: 0
Study 19547639 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation
Number of subjects: 152
Study 16686562 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics (PLYO)
Number of subjects: 19
Study 16686562 — intervention group
Group type: COMPARATOR
Intervention: Dynamic stabilization and balance training (BAL)
Number of subjects: 19
Study 14608552 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation and assertive skills training (8 group training sessions)
Number of subjects: 0
Study 14608552 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care treatment (control group)
Number of subjects: 0
Study 10999966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lined appliance
Number of subjects: 19
Study 10999966 — intervention group
Group type: COMPARATOR
Intervention: Unlined appliance
Number of subjects: 19
Study 8960720 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-DL-threo-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 11
Study 8960720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1578079 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐A condition (light therapy with UV-A wavelengths)
Number of subjects: 33
Study 1578079 — intervention group
Group type: COMPARATOR
Intervention: UV-blocked condition (light therapy without UV-A wavelengths)
Number of subjects: 33
Study 3933645 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulses followed by low dose oral prednisone for six months
Number of subjects: 89
Study 3933645 — intervention group
Group type: COMPARATOR
Intervention: High dose oral prednisone for four weeks followed by low dose oral prednisone for five months
Number of subjects: 89
Study 31071660 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoned high compression shorts (ZHC‐shorts)
Number of subjects: 34
Study 31071660 — intervention group
Group type: COMPARATOR
Intervention: Non‐zoned low compression shorts (NZLC‐shorts)
Number of subjects: 34
Study 31071660 — intervention group
Group type: COMPARATOR
Intervention: Normal sports clothes
Number of subjects: 34
Study 29795470 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD)
Number of subjects: 20
Study 29795470 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 29795470 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD and RYGB (combined)
Number of subjects: 20
Study 27531286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 62
Study 27531286 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid (dexamethasone 0.1% and tobramycin 0.3%) alone
Number of subjects: 62
Study 24485397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0
Study 24485397 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 0
Study 22335395 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of self‐monitored blood pressure, medicine review, a Digital Versatile Disc, and motivational interviewing telephone calls over 3 months.
Number of subjects: 75
Study 22335395 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 75
Study 20003697 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg daily for the first 2 months
Number of subjects: 150
Study 20003697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen plus daily 400 mg MXF
Number of subjects: 150
Study 20003697 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen alone (HERZ group)
Number of subjects: 150
Study 18568239 — intervention group
Group type: EXPERIMENTAL
Intervention: Urologist with 25 TURP procedures (Group I - 24 patients)
Number of subjects: 67
Study 18568239 — intervention group
Group type: EXPERIMENTAL
Intervention: Urologist with 50 TURP procedures (Group II - 24 patients)
Number of subjects: 67
Study 18568239 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior urologist with vast experience (Group III - 19 patients)
Number of subjects: 67
Study 18568239 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 67
Study 16652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine and stavudine
Number of subjects: 329
Study 16652032 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine plus efavirenz, nelfinavir, or both
Number of subjects: 329
Study 16652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 329
Study 12816895 — intervention group
Group type: EXPERIMENTAL
Intervention: Face perception
Number of subjects: 0
Study 12816895 — intervention group
Group type: EXPERIMENTAL
Intervention: Face recognition
Number of subjects: 0
Study 12816895 — intervention group
Group type: EXPERIMENTAL
Intervention: Face repetition
Number of subjects: 0
Study 10633648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program
Number of subjects: 11
Study 7477192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (t‐PA)
Number of subjects: 624
Study 7477192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 2318945 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 18
Study 2318945 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 18
Study 373124 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 32
Study 373124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 373124 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (after switching from placebo)
Number of subjects: 32
Study 30607782 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 long chain polyunsaturated fatty acids (722 mg docosahexaenoic acid)
Number of subjects: 73
Study 30607782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU daily)
Number of subjects: 73
Study 30607782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vitamin D and Omega-3 (VIDOM)
Number of subjects: 73
Study 30607782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 28182797 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback during gait retraining
Number of subjects: 16
Study 28182797 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjured individuals)
Number of subjects: 16
Study 25443863 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) - single session
Number of subjects: 28
Study 25443863 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE) - mean of 3.4 (median 2) interventions
Number of subjects: 28
Study 25443863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SIRT and TACE
Number of subjects: 28
Study 23379593 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program based on the Knowledge Enhances Your Safety (KEYS) program, adapted for the Australian context.
Number of subjects: 380
Study 23379593 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 380
Study 21150467 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m on days 1, 8, and 15) plus paclitaxel (180 mg/m on day 1) every 4 weeks (IP group)
Number of subjects: 78
Study 21150467 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (100 mg/m on days 1 and 8) plus gemcitabine (1000 mg/m on days 1 and 8) every 3 weeks (IG group)
Number of subjects: 78
Study 18999908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient messaging
Number of subjects: 100000
Study 18999908 — intervention group
Group type: COMPARATOR
Intervention: Physician messaging only (Control)
Number of subjects: 100000
Study 16720743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions in the community
Number of subjects: 0
Study 16720743 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12740043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1926
Study 12740043 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1926
Study 11435187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview version of the SF-12
Number of subjects: 106
Study 11435187 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire version of the SF-12
Number of subjects: 106
Study 9557177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training program (Group A, n = 20), 4 months duration
Number of subjects: 35
Study 9557177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training program (Group A, n = 20)
Number of subjects: 35
Study 9557177 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, n = 15)
Number of subjects: 35
Study 8011965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exodol
Number of subjects: 12
Study 8011965 — intervention group
Group type: COMPARATOR
Intervention: Dolac
Number of subjects: 12
Study 2595103 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (300 mg/kg body weight)
Number of subjects: 7
Study 2595103 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 (300 mg/kg body weight)
Number of subjects: 7
Study 4933388 — intervention group
Group type: EXPERIMENTAL
Intervention: DEAE Sephadex (12‐15 g/day)
Number of subjects: 0
Study 4933388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate + DEAE Sephadex
Number of subjects: 0
Study 4933388 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate + Cholestyramine
Number of subjects: 0
Study 7192075 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind food challenge in children suspected of being allergic to egg or milk (40 children tested)
Number of subjects: 126